In an opinion essay for STAT, reproductive-rights attorney Julie F. Kay argues that Heidi Overton, the nominee for FDA commissioner, would threaten access to mifepristone despite the drug's safety record. Kay says Overton's anti-abortion views are clear and that anti-abortion groups have celebrated her nomination as a chance to undermine the drug. At Thursday's Senate health committee hearing, Overton avoided direct answers on mifepristone and other topics, frustrating senators from both parties.
Kay points to mifepristone's long safety record: an estimated 7.5 million Americans have used it, and reported deaths are very low and not certainly attributable to the drug. Yet FDA rules require special clinician certification, pharmacy registration, and patient agreement forms. The essay contrasts this with acetaminophen, which is linked to about 458 deaths a year, and notes that birth control pills and emergency contraception are available over the counter.
The essay also describes ongoing legal fights. The Supreme Court threw out a 2024 challenge for lack of standing, but Louisiana has pursued restrictions on telemedicine abortion, and a 5th Circuit order briefly reinstated in-person dispensing before the Supreme Court paused it. Overton acknowledged that an FDA safety review of mifepristone would be on her desk and said she was eager to respond to Louisiana's litigation. The essay notes that a biotech CEO recently warned that letting courts and politicians second-guess FDA science endangers the drug pipeline.
This article is a single opinion essay rather than a news report, so no independent or contrasting sources are included.